Axsome Therapeutics, Inc. (AXSM) 2025年第一季度财报(10-Q)「NASDAQ」.pdf

1、Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31,2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCH

2、ANGE ACT OF 1934For the transition period from _ to _Commission File Number 001-37635 AXSOME THERAPEUTICS,INC.(Exact name of registrant as specified in its charter)Delaware45-4241907(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)One World Trade Cente

3、r29th FloorNew York,New York10007(Address of principal executive offices)(Zip Code)Registrants telephone number,including area code:(212)332-3241Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 du

4、ring the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File require

5、d to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months(or for such shorter period that the registrant was required to submit such files).Yes No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a s

6、maller reporting company,or an emerging growth company.See definitions of“large accelerated filer,”“accelerated filer,”“smaller reporting company”and“emerging growth company”in Rule 12b-2 of the Exchange Act.:Large accelerated filerAccelerated FilerNon-accelerated filerSmaller reporting company Emer